NEW YORK (Reuters Health) – Plaque radiotherapy is an effective therapy for managing iris melanoma in
certain patients and secondary glaucoma has no effect on outcomes, researchers have found.
Month: September 2012
Cloned EHR Notes Jeopardize Medicare Payment
Medicare contractors say they will recoup payment if they discover physicians are electronically recycling chart notes with no regard for accuracy. Medscape Medical News
Aflibercept Improves Visual Acuity in Patients With CRVO
Patients with central retinal vein occlusion (CRVO) achieved a significant improvement in visual acuity who aflibercept in 2 phase 3 clinical trials. Medscape Medical News
How Much Should Doctors REALLY Make?
Some doctors feel that politicians and consumers resent that docs make ‘too much money’ and that some people want doctors to earn less. Realistically speaking, how much should doctors be earning? Medscape Business of Medicine
pSivida reports revenues of $699,000 for fourth quarter 2012
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
Status: Recruiting,
Condition Summary: Glaucoma; Ocular Hypertension; Eye Disease
US FDA approves aflibercept injection (Eylea) for macular oedema following central retinal vein occlusion (CRVO)
Source: Reuters Health News
Area: News
According to a report by Reuters Health News, the US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea) for macular oedema following central retinal vein occlusion (CRVO). The recommend…
CHMP adopts positive opinion for aflibercept (Eylea) solution for injection for the treatment of wet age-related macular degeneration
Source: EMA
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product aflibercept (Eylea…
Ohr commences Phase II clinical trial of Squalamine for wet-AMD
Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.
Neuroprotection for Low-Tension Glaucoma?
The results are clear, even if the underlying mechanisms are not. Medscape Ophthalmology
Valeant purchases QLT’s Visudyne
Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.
Mathematicians Partner With IU Med School To Explore More Efficient Treatments
Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that cont…
Eye movement affects glaucomatous vision
Certain eye movement patterns seem to be associated with better face recognition performance in
patients with central glaucomatous visual field loss.
Intracorneal inlay now available in Canada
AcuFocus Inc. has received approval from Health Canada to market and sell the Kamra inlay, an
innovative corneal inlay to treat presbyopia, within Canada.
Besifloxacin ophthalmic suspension gains additional indications
The U.S. Food and Drug Administration has granted additional labeling indications for besifloxacin
ophthalmic suspension 0.6% eye drops (Besivance, Bausch + Lomb).
CLAO ERF, SSF to sponsor award for dry eye study
A scientific research grant to cover studies related to dry eye and ocular surface disease will be
awarded by CLAO ERF in association with the SSF.
Myopia May Protect Against Diabetic Retinopathy
Axial elongation may explain the possible protection from diabetic retinopathy observed in some studies of those with myopia. Medscape Medical News
FDA Approves Eylea for Macular Edema Following CRVO
The FDA decision expands the indication of the angiogenesis inhibitor, which is already approved for neovascular age-related macular degeneration. FDA Approvals
Urinary a-carboxyethyl hydroxychroman can be used as a predictor of a-tocopherol adequacy, as demonstrated in the Energetics Study
By: mtraber
An Added Benefit of Cataract Surgery: Fewer Hip Fractures
A new study finds a lower risk for hip fracture in patients who undergo cataract surgery vs those who do not. Dr. Roger Steinert discusses the findings and what they mean for your patients. Medscape Ophthalmology